key: cord-0860274-ezqjw8jq authors: Cazzaniga, Massimo; Fumagalli, Luca A. M.; D'angelo, Luciano; Cerino, Mario; Bonfanti, Giulia; Fumagalli, Riccardo M.; Schiavo, Gianpaolo; Lorini, Cristina; Lainu, Elisa; Terragni, Sabina; Chiarelli, Marco; Scarazzati, Claudio; Bonato, Claudio; Zago, Mauro title: Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID‐19 pneumonia date: 2021-02-05 journal: Int J Clin Pract DOI: 10.1111/ijcp.14047 sha: 1a4f0b387e7302a359c33b6745b204800da51e34 doc_id: 860274 cord_uid: ezqjw8jq BACKGROUND AND AIM: Viral pneumonia is the most relevant clinical presentation of COVID‐19 which may lead to severe acute respiratory syndrome and even death. Eosinopenia was often noticed in patients with COVID‐19 pneumonia, but its role is poorly investigated. The aim of the present study was to investigate the characteristics and clinical outcomes of patients with COVID‐19 pneumonia and eosinopenia. METHODS: We revised the records of consecutive patients with COVID‐19 pneumonia admitted to our ER‐COVID‐19 area in order to compare clinical characteristics and outcomes of patients with and without eosinopenia. We considered the following clinical outcomes: 4‐weeks survival; need for intensive respiratory support; and hospital discharge. RESULTS: Out of first 107 consecutive patients with pneumonia and a positive COVID‐19 nasopharyngeal swab, 75 patients showed undetectable eosinophil count (absolute eosinopenia). At 4 weeks, 38 patients (38.4%) had required intensive respiratory treatment, 25 (23.4%) deceased and 42 (39.2%) were discharged. Compared with patients without absolute eosinopenia, patients with absolute eosinopenia showed higher need of intensive respiratory treatment (49.3% vs 13.3%, P < .001), higher mortality (30.6% vs 6.2%, P .006) and lower rate of hospital discharge (28% vs 65.6%, P < .001). Binary logistic regression analyses including neutrophil, lymphocyte, eosinophil, basophil and monocyte counts showed that absolute eosinopenia was an independent factor associated with 4‐weeks mortality, need for intensive respiratory support and hospital discharge. CONCLUSIONS: Absolute eosinopenia is associated with clinical outcomes in patients with COVID‐19 pneumonia and might be used as a marker to discriminate patients with unfavourable prognosis. The clinical course of COVID-19 is variable with different and heterogeneous symptoms. Viral pneumonia is the most relevant clinical presentation of COVID-19 infection which may lead to severe acute respiratory syndrome (SARS) and even death. 1,2 COVID-19 has a significant impact on the hematopoietic system, and lymphopenia is a well-known characteristic in patients with COVID-19 infection. 1 The dysregulation of hematologic and immunologic systems seems to play a key role in the pathological process of COVID-19 infection and, finally, in evolution of disease. Some authors provided demonstration about impairment of immune response especially of T lymphocytes and the derangement of excessive inflammatory response. 3 Remarkable eosinopenia was often noticed both in patients with and without severe disease but its role is poorly investigated. 3, 4 The aim of the present study was to investigate the characteristics and clinical outcomes of patients with COVID-19 pneumonia and eosinopenia. Since 27 February 2020 following a regional alert about outbreak in Lombardia (Italy), our hospital set up a dedicated area in our emergency department (ER-COVID-19 area), where patients underwent diagnostic procedures, appropriated treatments and, then, transferred to COVID-19-dedicated wards, Intensive Units or discharged. We revised the records of consecutive patients with COVID-19 pneumonia admitted to our ER-COVID-19 area in order to compare demographic, biochemical, radiological and clinical characteristics at hospital admission and outcomes of patients with and without eosinopenia. We excluded patients younger than 18 years old and patients transferred from other hospitals. We considered the following clinical outcomes: 4-weeks survival; need for intensive respiratory support (high-flow nasal cannula oxygen support, non-invasive ventilation and/or mechanical ventilation); and hospital discharge. The study was performed according to the Declaration of Helsinki, and written informed consent was obtained from all the patients. All data were anonymised. Qualitative and quantitative data are reported as frequencies and means ± standard deviation (min-max) or median and range as appropriated, respectively. Non-parametric test was used to compare independent groups. Univariate and multivariate analyses were performed by logistic regression analyses. Sensitivity, specificity, predictive values and likelihood ratios were calculated by conventional formulas in order to predict in-hospital mortality. Two-sided statistical tests were used for all analyses; a P value of <.05 was considered significant. Jamovi software was used for statistical analyses. Patients with absolute eosinopenia were older and had higher age-adjusted Charlson comorbidity index (an accurate score to define the weight of comorbidity) with respect to patients without absolute eosinopenia. A clinically severe disease with lower values of pulse oxymeter saturation was more frequent in patients with absolute eosinopenia who showed a significantly higher values of C-reactive protein and lower counts of lymphocytes, basophils, monocytes and platelet than patients without absolute eosinopenia (Table 1) . At 4 weeks, 38 patients (38.4%) had required intensive respiratory treatment, 25 (23.4%) deceased and 42 (39.2%) were discharged. The need of intensive respiratory treatment and mortality were significantly worse in patients with absolute eosinopenia compared with patients without absolute eosinopenia (49.3% vs 13.3%, P < .001 and 30.6% vs 6.2%, P .006, respectively), whereas the rates of hospital discharges were significantly lower in patients with absolute eosinopenia with respect to those without (28% vs 65.6%, P < .001) ( Table 1) However, the relationship between eosinopenia and clinical outcomes is unknown. • The present study confirms that eosinopenia is frequent in patients with COVID-19 pneumonia. • Absolute eosinopenia is significantly associated with unfavourable clinical outcomes, namely need of intensive respiratory treatment and mortality and its relationship is independent from other leukocytes. • Absolute eosinopenia showed good sensitivity and negative predictive values in predicting unfavourable outcomes suggesting that it is a useful marker in patients with COVID-19 pneumonia. predicting hospital discharge were 50%, 17%, 28%, 34%, 0.6 and 3.0, respectively. .73 White blood cell count (10 9 /L) 6.3 ± 3.1 (1.9-18.6) 6.2 ± 2.9 (2.9-18.6) 6.7 ± 3.5 (1.9-17.9) .42 Neutrophil count (10 9 /L) 4.7 Monocyte count (10 9 /L) 0.51 ± 0. were used to compare groups. b CAaCI: age-adjusted Charlson comorbidity index. c Clinically severe disease: concurrent presence of: fever >38°C; lower respiratory symptoms (cough, difficulty breathing, shortness of breath, high respiratory rate) and radiographic evidence of lung infiltrates consistent with interstitial pneumonia or Acute Respiratory Distress Syndrome. Nevertheless, our results support the clinical usefulness of absolute eosinopenia as a marker to predict patients with unfavourable outcomes in an emergency setting, although these findings should be validated in independent cohorts. None of Authors has anything to disclose. We confirm that this manuscript has not been published elsewhere and is not under consideration by another journal. TA B L E 2 Logistic regression analysis including neutrophil, lymphocyte, eosinophil, basophil and monocyte counts to identify leukocytes independently associated with: (A) mortality; (B) need for intensive respiratory treatment; (C) hospital discharge in patients with COVID-19 pneumonia Variables A mortality Neutrophil count (10 9 /L) 4.0 10 9 /L 4.77 (1.56-14.5) .006 Lymphocyte count (10 9 /L) 1.0 10 9 /L 2.06 (0.70-6.04) .18 Eosinophil count (10 9 /L) 0.0 10 9 /L 5.65 (1.15-27.6) .032 Basophil count 10 9 /L) 0.01 10 9 /L 1.25 (0.38-4.11) .71 Monocyte count (10 9 /L) 0.5 10 9 /L 1.65 (0.53-5.11) .18 Odds ratio 95% confidence interval P value Neutrophil count (10 9 /L) 4.0 10 9 /L 2.64 (0.98-7.10) .054 Lymphocyte count (10 9 /L) 1.0 10 9 /L 1.17 (0.43-3.2) .74 Eosinophil count (10 9 /L) 0.0 10 9 /L 4.09 (1.16-14.3) .028 Basophil count 10 9 /L) 0.01 10 9 /L 2.05 (0.63-6.67) .23 Monocyte count (10 9 /L) 0.5 10 9 /L 3.86 (1.33-11.2) .013 Odds ratio 95% confidence interval P value Neutrophil count (10 9 /L) 4.0 10 9 /L 0.47 (0.18-1.19) .11 Lymphocyte count (10 9 /L) 1.0 10 9 /L 0.76 (0.29-1.97) .57 Eosinophil count (10 9 /L) 0.0 10 9 /L 0.28 (0.11-0.73) .010 Basophil count 10 9 /L) 0.01 10 9 /L 0.34 (0.08-1.44 .14 Monocyte count (10 9 /L) 0.5 10 9 /L 0.49 (018-1.29) .15 a Eight agonic patients treated by palliation were excluded from this analysis. Severe covid-19 Dysregulation of immune response in patients with COVID-19 in Wuhan, China Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study Biology of the eosinophil Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia